Naveen Babbar
Overview
Explore the profile of Naveen Babbar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferrarotto R, Swiecicki P, Zandberg D, Baiocchi R, Wesolowski R, Rodriguez C, et al.
Oral Oncol
. 2023 Dec;
149:106634.
PMID: 38118249
Objectives: Currently, no systemic treatments are approved for patients with recurrent and/or metastatic (R/M) adenoid cystic carcinoma (ACC). PRT543, a protein arginine methyltransferase 5 inhibitor that downregulates NOTCH1 and MYB...
2.
Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, et al.
BMC Med
. 2023 Aug;
21(1):306.
PMID: 37580773
Background: There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a longitudinal ctDNA...
3.
Bardia A, Su F, Solovieff N, Im S, Sohn J, Lee K, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34504990
Purpose: This analysis evaluated the genomic landscape of premenopausal patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and the association of genetic alterations with...
4.
Prat A, Chaudhury A, Solovieff N, Pare L, Martinez D, Chic N, et al.
J Clin Oncol
. 2021 Mar;
39(13):1458-1467.
PMID: 33769862
Purpose: The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently...
5.
OBrien N, McDermott M, Conklin D, Luo T, Ayala R, Salgar S, et al.
Breast Cancer Res
. 2020 Aug;
22(1):89.
PMID: 32795346
Background: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2- breast cancer. However, acquired resistance to these therapies frequently leads to disease...
6.
Bertucci F, Ng C, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al.
Nature
. 2019 Jul;
572(7767):E7.
PMID: 31308536
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Bertucci F, Ng C, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al.
Nature
. 2019 May;
569(7757):560-564.
PMID: 31118521
Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence...
8.
Mayer I, Prat A, Egle D, Blau S, Fidalgo J, Gnant M, et al.
Clin Cancer Res
. 2019 Feb;
25(10):2975-2987.
PMID: 30723140
Purpose: Addition of alpelisib to fulvestrant significantly extended progression-free survival in -mutant, hormone receptor-positive (HR) advanced/metastatic breast cancer in the phase III SOLAR-1 study. The combination of alpelisib and letrozole...
9.
Jones J, Wilcox B, Benz R, Babbar N, Boragine G, Burrell T, et al.
Clin Colorectal Cancer
. 2016 May;
15(2):186-194.e13.
PMID: 27237338
Introduction: Colorectal cancer (CRC) testing programs reduce mortality; however, approximately 40% of the recommended population who should undergo CRC testing does not. Early colon cancer detection in patient populations ineligible...
10.
Babbar N, Gerner E
Recent Results Cancer Res
. 2011 Jan;
188:49-64.
PMID: 21253788
Increased polyamine synthesis and inflammation have long been associated with intraepithelial neoplasia, which are risk factors for cancer development in humans. Targeting polyamine metabolism (by use of polyamine synthesis inhibitors...